{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:45:34Z","timestamp":1787798734667,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","surgjournal.com","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.surg.2024.07.026","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:33:26Z","timestamp":1724733206000},"page":"1458-1465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence"],"prefix":"10.1016","volume":"176","author":[{"given":"Domenico","family":"Tamburrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-0307","authenticated-orcid":false,"given":"Federico","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Belfiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Macchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavo Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Doglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-7243","authenticated-orcid":false,"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2024.07.026_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2024.07.026_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2024.07.026_bib3","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.pan.2023.06.005","article-title":"\u201cConversion surgery\u201d for locally advanced pancreatic cancer: a position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022","volume":"23","author":"Oba","year":"2023","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2024.07.026_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/SLA.0000000000002557","article-title":"The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma","volume":"269","author":"Ghaneh","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1477-2574.2008.00013.x","article-title":"Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP)","volume":"11","author":"Menon","year":"2009","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2024.07.026_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pan.2018.04.010","article-title":"Pathology assessment of pancreatic cancer following neoadjuvant treatment: time to move on","volume":"18","author":"Verbeke","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2024.07.026_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","article-title":"Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?","volume":"268","author":"He","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/0284186X.2016.1256497","article-title":"Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy","volume":"56","author":"Mellon","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamasurg.2017.2227","article-title":"Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma","volume":"152","author":"Cloyd","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib12","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1245\/s10434-015-4783-x","article-title":"Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEO-FRENCH, prospective, multicentric cohort","volume":"22","author":"Pietrasz","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib13","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s11605-020-04697-1","article-title":"Is complete pathologic response in pancreatic cancer overestimated? A systematic review of prospective studies","volume":"24","author":"Laura","year":"2020","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.surg.2024.07.026_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.athoracsur.2008.11.001","article-title":"Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival","volume":"87","author":"Donahue","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-009-0862-1","article-title":"Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer","volume":"17","author":"Meredith","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib19","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1245\/s10434-010-1506-1","article-title":"Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence","volume":"18","author":"de Campos-Lobato","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.hpb.2018.08.013","article-title":"Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer","volume":"21","author":"Bolton","year":"2019","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2024.07.026_bib21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.hpb.2020.01.013","article-title":"Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes","volume":"22","author":"Cloyd","year":"2020","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2024.07.026_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.anndiagpath.2011.08.005","article-title":"Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis","volume":"16","author":"Zhao","year":"2012","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.surg.2024.07.026_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/SLA.0000000000003570","article-title":"Recurrence in patients achieving pathological complete response after neoadjuvant treatment for advanced pancreatic cancer","volume":"274","author":"Blair","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100238","article-title":"Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey","volume":"6","author":"Orsi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.surg.2024.07.026_bib25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","article-title":"BRCA1\/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma","volume":"226","author":"Blair","year":"2018","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.6004\/jnccn.2019.0014","article-title":"Guidelines insights: pancreatic adenocarcinoma, version 1.2019","volume":"17","author":"Tempero","year":"2019","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.surg.2024.07.026_bib28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/cancers12061681","article-title":"Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM)","volume":"12","author":"Silvestris","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.surg.2024.07.026_bib29","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1007\/s11605-023-05848-w","article-title":"Surgical planning for \u201cborderline resectable\u201d and \u201clocally advanced\u201d pancreatic cancer during open pancreatic resection","volume":"27","author":"Tamburrino","year":"2023","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.ejso.2023.03.229","article-title":"Pancreatectomy with venous vascular resection for pancreatic cancer: impact of types of vein resection on timing and pattern of recurrence","volume":"49","author":"Tamburrino","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/bjs\/znab133","article-title":"Technical advances in surgery for pancreatic cancer","volume":"108","author":"Schneider","year":"2021","journal-title":"Br J Surg"},{"key":"10.1016\/j.surg.2024.07.026_bib32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers","volume":"25","author":"Chun","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib33","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1245\/s10434-022-11413-7","article-title":"Proposal for a new pathologic prognostic index after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma (PINC)","volume":"29","author":"Redegalli","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2018.07.007","article-title":"A\u00a0randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma","volume":"102","author":"Reni","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.surg.2024.07.026_bib35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/MPA.0000000000001590","article-title":"Evaluation of pathologic response on overall survival after neoadjuvant therapy in pancreatic ductal adenocarcinoma","volume":"49","author":"Sell","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.surg.2024.07.026_bib36","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib37","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","article-title":"A\u00a0prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma","volume":"26","author":"Eguchi","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib38","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002168","article-title":"Pathological complete remission of pancreatic cancer following neoadjuvant chemoradiation therapy; not the end of battles","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.surg.2024.07.026_bib40","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/COC.0000000000000409","article-title":"Clinical characteristics of patients experiencing pathologic complete response following neoadjuvant therapy for borderline resectable\/locally\u00a0advanced pancreatic adenocarcinoma","volume":"41","author":"Hashemi-Sadraei","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.surg.2024.07.026_bib42","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1245\/s10434-020-08469-8","article-title":"Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer","volume":"27","author":"Golan","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2024.07.026_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100032","article-title":"Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort","volume":"6","author":"Peretti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.surg.2024.07.026_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","article-title":"Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy","volume":"34","author":"Janssen","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606024005440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606024005440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T13:43:22Z","timestamp":1737294202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606024005440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0039606024005440"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2024.07.026","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2024.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}